Chemed Corp. (NYSE:CHE) insider Nicholas Michael Westfall sold 10,000 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $231.00, for a total value of $2,310,000.00. Following the sale, the insider now directly owns 13,351 shares of the company’s stock, valued at $3,084,081. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Shares of Chemed Corp. (NYSE:CHE) opened at $232.42 on Thursday. The company has a quick ratio of 0.48, a current ratio of 0.50 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $3,700.76, a P/E ratio of 28.55, a PEG ratio of 4.90 and a beta of 1.14. Chemed Corp. has a 1-year low of $145.09 and a 1-year high of $235.96.

Chemed Corp. (NYSE:CHE) last posted its quarterly earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating the consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million during the quarter, compared to analysts’ expectations of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the firm earned $1.73 EPS. sell-side analysts anticipate that Chemed Corp. will post 4.73 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 4th. Stockholders of record on Monday, November 13th will be issued a $0.28 dividend. The ex-dividend date of this dividend is Friday, November 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.48%. Chemed Corp.’s dividend payout ratio is currently 24.89%.

TRADEMARK VIOLATION WARNING: “Nicholas Michael Westfall Sells 10,000 Shares of Chemed Corp. (CHE) Stock” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/16/nicholas-michael-westfall-sells-10000-shares-of-chemed-corp-che-stock.html.

Several institutional investors and hedge funds have recently bought and sold shares of CHE. Teachers Advisors LLC lifted its holdings in shares of Chemed Corp. by 3.0% in the 1st quarter. Teachers Advisors LLC now owns 30,431 shares of the company’s stock valued at $5,559,000 after buying an additional 894 shares during the period. State Street Corp lifted its holdings in shares of Chemed Corp. by 9.1% in the 1st quarter. State Street Corp now owns 445,367 shares of the company’s stock valued at $81,370,000 after buying an additional 37,085 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Chemed Corp. by 10.6% in the 1st quarter. AQR Capital Management LLC now owns 16,514 shares of the company’s stock valued at $3,017,000 after buying an additional 1,576 shares during the period. Capstone Asset Management Co. lifted its holdings in shares of Chemed Corp. by 2.7% in the 2nd quarter. Capstone Asset Management Co. now owns 1,857 shares of the company’s stock valued at $380,000 after buying an additional 49 shares during the period. Finally, Bank of Montreal Can lifted its holdings in shares of Chemed Corp. by 2.4% in the 2nd quarter. Bank of Montreal Can now owns 3,311 shares of the company’s stock valued at $677,000 after buying an additional 77 shares during the period. 96.58% of the stock is owned by institutional investors and hedge funds.

A number of analysts have weighed in on CHE shares. KeyCorp reaffirmed a “hold” rating on shares of Chemed Corp. in a research report on Friday, October 27th. Zacks Investment Research cut Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Royal Bank Of Canada reaffirmed a “hold” rating and set a $209.00 price objective on shares of Chemed Corp. in a research report on Tuesday, October 3rd. BidaskClub cut Chemed Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Oppenheimer Holdings, Inc. increased their price objective on Chemed Corp. from $220.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $236.00.

Chemed Corp. Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Insider Buying and Selling by Quarter for Chemed Corp. (NYSE:CHE)

Receive News & Stock Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related stocks with our FREE daily email newsletter.